Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 20 mg/ml - solution for injection - 20 mg/ml - active: cytarabine 20 mg/ml excipient: sodium chloride water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - nevirapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; povidone - nevirapine viatris in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults. resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Spojené štáty - angličtina - NLM (National Library of Medicine)

fresenius kabi usa, llc - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine 100 mg in 1 ml - cytarabine injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. it has also been found useful in the treatment of acute non-lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.

Európska únia - angličtina - EMA (European Medicines Agency)

teva b.v.  - nevirapine - hiv infections - antivirals for systemic use - nevirapine teva is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv 1 infected adults, adolescents, and children of any age.most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (nrtis). the choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.

Spojené štáty - angličtina - NLM (National Library of Medicine)

macleods pharmaceuticals limited - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults and pediatric patients 15 days and older [see clinical studies (14.1, 14.2)]. limitations of use: based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine tablets  is not recommended to be initiated, unless the  benefit outweighs the risk, in: • adult females with cd4+ cell counts greater than 250 cells/mm3 or • adult males with cd4+ cell counts greater than 400 cells/mm3 [see warnings and precautions (5.1)]. nevirapine  is contraindicated: • in patients with moderate or severe (child-pugh class b or c, respectively) hepatic impairment [see warnings and precautions (5.1) and use in specific populations (8.7)]. • for use as part of occupational and non-occupational post-exposure prophylaxis (pep) regimens [see warnings and precautions (5.1)]. pregnancy exposure registry

Keňa - angličtina - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - nevirapine tablets for oral suspension 50mg - tablet - nevirapine - 50mg - nevirapine

Malta - angličtina - Medicines Authority

hospira uk limited - cytarabine - solution for injection - cytarabine 100 mg/5ml - antineoplastic agents

Malta - angličtina - Medicines Authority

hospira uk limited - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents

Malta - angličtina - Medicines Authority

hospira uk limited - cytarabine - solution for injection - cytarabine 100 mg/5ml - antineoplastic agents

Malta - angličtina - Medicines Authority

hospira uk limited - cytarabine - solution for injection - cytarabine 100 mg/5ml - antineoplastic agents